John W. Smith, MD

📹BETWEEN THE LINES: Discover how a novel treatment for atopic dermatitis is shaping the standard of care and evolving treatment paradigms. Gain insights from Lawrence Eichenfield, MD, and elevate your clinical practice: https://ow.ly/eulJ50TOUpN

3

In the rare disease space, every launch decision counts. Transform complexity into a strategy to navigate expedited pathways, manage risk, and avoid launch delays. Hear from our experts Kapil Raina, Brian Williams, and Chris Zealey: https://lnkd.in/eYHYwDS5 #MarketAccess #MedicalAffairs #LaunchExcellence #AskHerspiegel

6

Joyce O’Shaughnessy, MD, will present new #FLEX data at #ASCO24 focused on 3-year outcomes of patients with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer when treated with two different chemotherapy regimens. "The ability to tailor treatment regimens to a patient’s tumor biology is crucial to optimize outcomes and quality of life. MammaPrint's utility in guiding treatment planning is highlighted by these new data evaluating chemotherapy selection," said Dr. O'Shaughnessy. "The FLEX Study and sub-studies, such as this one, enable increased precision in identifying patients that are more responsive to specific systemic therapy regimens, and continue to aid selection of treatments for patients with HR+/HER2-negative early-stage breast cancer." Attend Dr. O'Shaughnessy’s Rapid Oral Presentation on May 31st at 2:45pm-4:15pm CT. Read the full release: https://lnkd.in/gx6yymrQ #Oncology #BreastCancer #MammaPrint Attend May 31st at 2:45pm - 4:15pm CT.

26

Whether you're getting started in lung cancer patient advocacy or already a seasoned pro, you'll want to watch this video with Jill Feldman and Dusty Donaldson. Called, "Learning from the legends of lung cancer advocacy," this discussion covers everything from top tips, working with others, resources & more. This video is part 2 of a 3-part series from our Co-founder and Chair, Yvonne Diaz, following the award of an IASLC Patient Educational Award. Don't miss this: 📺 https://lnkd.in/ex5UmW2C #PatientAdvocacy #lungcancer #hope #PatientVoice #StrongerTogether

6

2 Comments

If we find the right therapy, shares Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO, there are patients who reach a functional cure and may never need a myeloma treatment. In honor of Blood Cancer Awareness Month, share your experience with remission! #kNOwMyeloma

96

3 Comments

What do patients really talk about behind closed doors? Inspire is proud to join a panel of patient engagement experts at the 2025 SCOPE conference to explore how we can amplify all patient voices—not just the ones you see on the podium. This session will dive into critical questions: 🔹 How can clinical trials and RWE efforts better engage underrepresented patients? 🔹 What barriers prevent equitable access to patient conversations, and how can they be addressed? 🔹 How can we move beyond misconceptions to ensure patient stories reflect the full diversity of lived experiences? If you’re designing clinical trials or developing patient engagement strategies, this session is an opportunity to learn how we can create more inclusive, authentic, and impactful outcomes for all patients. Let’s rethink how we connect with our communities and ensure every voice is heard. See you there! 📅 Date: Monday, February 3 ⏰ Time: 4:35 - 5:05 PM 📍 Session Title: Behind Closed Doors: What Do Patients Really Talk About? #SCOPE2025 #PatientEngagement

55

1 Comment

Our experts constantly innovate to enroll the right patients and improve data quality in #lupus #clinicaltrials. Your trial needs subjects with the appropriate disease activity and should also reflect the #diverse target patient population. » https://bit.ly/47vQhJl

41

‘Spotlight on Autoimmunity’ series: Potential New Frontiers in the Treatment of Lupus Nephritis, by Dr. Rich Furie. Learn about current management of #lupusnephritis and how current clinical trials are evaluating novel therapeutic approaches to address unmet needs. #lupuswarrior #autoimmunedisease #KYV-101 https://lnkd.in/gsAnWCs5

66

🗞️👓 New on the Catalyst Clinical Research Blog: Highlights from hubXchange Immunotherapies Maryland 2024! 📖 Catalyst Clinical Research was excited to share insights from this year’s hubXchange Immunotherapies Maryland 2024, where their Executive Director, Meredith M., joined industry experts to address the latest advancements and challenges in immunotherapy trials. This exclusive event covered everything from optimizing dosing strategies to leveraging cutting-edge biomarkers for improved patient safety and efficacy. In Meredith's keynote presentation and “Project Optimus” roundtable, Meredith led discussions on the FDA’s dose optimization guidance, emphasizing the shift toward minimally and maximally effective doses for early-phase trials. Catalyst also explored how PK-PD modeling is reshaping dose-response understanding, while advanced biomarkers are offering new ways to monitor immunotherapy impact and safety. Visit the blog to see how Catalyst is helping shape the future of immuno-oncology through tailored solutions that drive safety and efficacy in clinical trials. 👀 Read the full article: https://lnkd.in/eJtQB4jP 🌐 https://lnkd.in/e8pDqkji #Immunotherapy #PatientSafety #ClinicalTrials #CatalystOncology #HubXchange

35

1 Comment

When it comes to lung cancer treatment, access isn’t always equal. Studies reveal that Black patients are 10-15% less likely to receive surgery for lung cancer—even when they’re eligible. This disparity isn’t just a statistic; it’s a matter of life and equality. Every patient deserves fair access to treatment options that can save lives. Together, we must raise awareness, challenge biases, and advocate for equitable healthcare for all. This is why FM2U is here, were here to support you and advocate for you do that we can bridge the gap in cancer care. Share this post to help spread the word. 💙 #LungCancerAwareness #HealthEquity #FromMeToYouUK #EqualCare #EndDisparities #CancerCareForAll

3

Louise Rodino-Klapac, PhD, our executive vice president, chief scientific officer and head of Research and Development, comments on the news that enrollment and dosing is complete in EMERGENE (Study SRP-9003-301), a Phase 3 clinical trial of SRP-9003 (bidridistrogene xeboparvovec). SRP-9003 is an investigational gene therapy for the treatment of limb-girdle muscular dystrophy Type 2E/R4 (LGMD2E/R4). Data are expected in the first half of 2025.

219

2 Comments

At Stiris, we are at the forefront of ALS clinical trials. Our experienced team is dedicated to advancing research and finding effective treatments for ALS, and through a patient-centered approach, we ensure world-class care and support for patients. Learn more at www.stirisresearch.com #ALS #ClinicalResearch #StirisResearch #ALSAwarenessMonth

17

While #ASCO24 is at an end, it was great following all of it on social media. If you were at ASCO and interested in potential collaborations with the journal Technology in Cancer Research & Treatment, please feel free to reach out. Thanks for sharing OncoDaily! #cancer #oncology #cancerresearch #oncodaily

5

🎙️ In this episode of Bladder Cancer Matters, host Rick Bangs is joined by Dr. Ashish Kamat from MD Anderson Cancer Center to discuss the latest breakthroughs in bladder cancer treatment. They dive deep into the effectiveness of BCG, the ongoing shortage, and exciting new alternatives like gene therapy, Pembrolizumab, and ANKTIVA. Dr. Kamat offers valuable insights into how these therapies are reshaping the future of bladder cancer care, focusing on personalized treatment and shared decision-making. Whether you're a patient, caregiver, or healthcare professional, this episode is packed with must-know information. Click the link and listen now! https://lnkd.in/gi25wZH8

6

🎙️ In this episode of Bladder Cancer Matters, host Rick Bangs is joined by Dr. Ashish Kamat from MD Anderson Cancer Center to discuss the latest breakthroughs in bladder cancer treatment. They dive deep into the effectiveness of BCG, the ongoing shortage, and exciting new alternatives like gene therapy, Pembrolizumab, and ANKTIVA. Dr. Kamat offers valuable insights into how these therapies are reshaping the future of bladder cancer care, focusing on personalized treatment and shared decision-making. Whether you're a patient, caregiver, or healthcare professional, this episode is packed with must-know information. Click the link and listen now! https://lnkd.in/gi25wZH8

3